Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

90 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The antiviral activity of Toll-like receptor 7 and 7/8 agonists.
Miller RL, Meng TC, Tomai MA. Miller RL, et al. Among authors: meng tc. Drug News Perspect. 2008 Mar;21(2):69-87. doi: 10.1358/dnp.2008.21.2.1188193. Drug News Perspect. 2008. PMID: 18389099 Review.
An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma.
Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, Skalsky J, Kaehler KC, Moosbauer S, Clark R, Meng TC, Urosevic M. Dummer R, et al. Among authors: meng tc. Clin Cancer Res. 2008 Feb 1;14(3):856-64. doi: 10.1158/1078-0432.CCR-07-1938. Clin Cancer Res. 2008. PMID: 18245549 Clinical Trial.
Cutaneous pharmacodynamics of a toll-like receptor 7 agonist, 852A, in humans.
Astry C, Birmachu W, Harrison LI, Meng TC. Astry C, et al. Among authors: meng tc. J Clin Pharmacol. 2008 Jun;48(6):755-62. doi: 10.1177/0091270008314466. Epub 2008 Apr 9. J Clin Pharmacol. 2008. PMID: 18401016 Clinical Trial.
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.
Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S. Adams S, et al. Among authors: meng tc. Clin Cancer Res. 2012 Dec 15;18(24):6748-57. doi: 10.1158/1078-0432.CCR-12-1149. Epub 2012 Jul 5. Clin Cancer Res. 2012. PMID: 22767669 Free PMC article. Clinical Trial.
Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children.
Myhre PE, Levy ML, Eichenfield LF, Kolb VB, Fielder SL, Meng TC. Myhre PE, et al. Among authors: meng tc. Pediatr Dermatol. 2008 Jan-Feb;25(1):88-95. doi: 10.1111/j.1525-1470.2007.00590.x. Pediatr Dermatol. 2008. PMID: 18304162 Clinical Trial.
Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC. Quirk C, et al. Among authors: meng tc. Cutis. 2010 Jun;85(6):318-24. Cutis. 2010. PMID: 20666194 Clinical Trial.
Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study.
Bernstein DI, Spruance SL, Arora SS, Schroeder JL, Meng TC. Bernstein DI, et al. Among authors: meng tc. Clin Infect Dis. 2005 Sep 15;41(6):808-14. doi: 10.1086/432802. Epub 2005 Aug 10. Clin Infect Dis. 2005. PMID: 16107978 Clinical Trial.
Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.
Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng TC. Pockros PJ, et al. Among authors: meng tc. J Hepatol. 2007 Aug;47(2):174-82. doi: 10.1016/j.jhep.2007.02.025. Epub 2007 May 4. J Hepatol. 2007. PMID: 17532523 Clinical Trial.
A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses.
Jorizzo JL, Markowitz O, Lebwohl MG, Bourcier M, Kulp J, Meng TC, Levy S. Jorizzo JL, et al. Among authors: meng tc. J Drugs Dermatol. 2010 Sep;9(9):1101-8. J Drugs Dermatol. 2010. PMID: 20865842 Clinical Trial.
Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.
Kulp J, Levy S, Fein MC, Adams M, Furst J, Meng TC. Kulp J, et al. Among authors: meng tc. Arch Dermatol Res. 2010 Sep;302(7):539-44. doi: 10.1007/s00403-010-1041-8. Epub 2010 Mar 4. Arch Dermatol Res. 2010. PMID: 20204654 Clinical Trial.
90 results
Jump to page